(1'R,2S,2'S,3'R,5'R,7'S,10'S,11'R,18'R)-7',11'-dimethyl-5,14'-dioxospiro[oxolane-2,6'-pentacyclo[8.8.0.02,7.03,5.011,16]octadec-15-ene]-18'-carbonitrile | 97869-73-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (1'R,2S,2'S,3'R,5'R,7'S,10'S,11'R,18'R)-7',11'-dimethyl-5,14'-dioxospiro[oxolane-2,6'-pentacyclo[8.8.0.02,7.03,5.011,16]octadec-15-ene]-18'-carbonitrile
• CAS: 97869-73-3
• 化学式: C₂₄H₂₉NO₃
• 分子量: 379.499
• InChiKey: YIZRPYUYQMZGQA-QOBLXKTDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28.0
• 可旋转键数：
  0.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  67.16
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (1'R,2S,2'S,3'R,5'R,7'S,10'S,11'R,18'R)-7',11'-dimethyl-5,14'-dioxospiro[oxolane-2,6'-pentacyclo[8.8.0.02,7.03,5.011,16]octadec-15-ene]-18'-carbonitrile 生成 (1'R,2S,2'S,3'R,5'R,7'S,10'S,11'R,14'S,18'R)-5,14'-dihydroxy-7',11'-dimethylspiro[oxolane-2,6'-pentacyclo[8.8.0.02,7.03,5.011,16]octadec-15-ene]-18'-carbaldehyde
  参考文献：
  名称：

  NICKISCH, K.;LAURENT, H.;ESPERLING, P.;BITTLER, D.;WIECHERT, R.;LOSERT, W+

  摘要：

  DOI：
• 作为产物：
  描述：

  (1'S,2'S,3'R,5S,5'R,7'S,10'S,11'R)-7',11'-dimethylspiro[oxolane-5,6'-pentacyclo[8.8.0.02,7.03,5.011,16]octadeca-15,17-diene]-2,14'-dione 、 二乙基氰化铝 生成 (1'R,2S,2'S,3'R,5'R,7'S,10'S,11'R,18'R)-7',11'-dimethyl-5,14'-dioxospiro[oxolane-2,6'-pentacyclo[8.8.0.02,7.03,5.011,16]octadec-15-ene]-18'-carbonitrile
  参考文献：
  名称：

  NICKISCH, K.;LAURENT, H.;ESPERLING, P.;BITTLER, D.;WIECHERT, R.;LOSERT, W+

  摘要：

  DOI：

文献信息

• Aldosterone antagonists. 3. Synthesis and activities of steroidal 7.alpha.-(alkoxycarbonyl)-15,16-methylene spirolactones
  作者：Klaus Nickisch、Dieter Bittler、Henry Laurent、Wolfgang Losert、Yukishige Nishino、Ekkehard Schillinger、Rudolf Wiechert

  DOI：10.1021/jm00164a007

  日期：1990.2

  Several A- and D-ring substituted steroidal 7 alpha-alkoxycarbonyl spirolactones were synthesized with the purpose of increasing the aldosterone antagonistic potency and reducing the endocrinological side effects relative to the standard drug spironolactone. It was found that the 15 beta,16 beta-methylene derivative 17 exhibited a 2-fold higher aldosterone antagonistic activity compared to either spironolactone

  相对于标准药物螺内酯，合成了几种A和D环取代的甾体7α-烷氧基羰基螺内酯，目的是增加醛固酮的拮抗力并减少内分泌副作用。已经发现，与螺内酯或15，16-未取代的衍生物29相比，15β，16β-亚甲基衍生物17表现出高两倍的醛固酮拮抗活性，同时显示出显着降低的抗雄激素性。